Low Intensity Knee Gonalgia
Conditions
Keywords
Joint discomfort, Functional Food, Joint function, Mobilee
Brief summary
The purpose of this study is to determine whether the daily eating of a yogurt supplemented with Mobile is effective in improving joint function and quality of life of individuals with low intensity gonalgia.
Detailed description
The prevalence of low intensity gonalgia is relatively high in western population. The purpose of the present intervention study is to determine whether the daily consumption of a yogurt supplemented with Mobile is effective in improving joint function and quality of life of individuals with low intensity gonalgia. Previous research using in vitro and animal models have demonstrated the efficacy of Mobilee in reducing inflammation and promoting anabolic responses in joint tissues. In addition, in two previous human intervention trials, the effects of Mobilee in joint function had been assessed using isokinetic tests. The present trial aims to confirm those previous results.
Interventions
DIETARY_SUPPLEMENTYogurt supplemented with Mobilee
One yogurt (125mL) per day including 80mg of Mobilee
DIETARY_SUPPLEMENTYogurt
One yogurt (125mL) per day
Sponsors
Technological Centre of Nutrition and Health
Bioiberica
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
20 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult (between 20 and 70 years of age) * Subject with low intensity knee gonalgia (VAS pain intensity between 3 and 5cm during at least the last 6 months) * Healthy individual according to its medical records, physical and laboratorial parameters * Positive informed consent
Exclusion criteria
* Individuals requiring acetaminophen or any other drug to control pain * Active rheumatoid arthritis or any other inflammatory joint disease * Oral treatment with corticosteroids 4 weeks before selection * Intra-articular treatment with corticosteroids 3 months before selection * Significant injury of the study joint 12 months before selection * Individuals receiving any drug or supplement for osteoarthritis * Individuals requiring any type of medical prescription to control pain
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in isokineic assessment of muscular strength | 3 months | The muscular isokinetic assessment determines peak torque, power mean and total work of a certain joint using a dynamometric computerized system. The principal parameter is the change from baseline in the peak torque of the affected joint in extension at a speed of 240º/sec measured in Nm (Newton-meter). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of joint swelling, effusion | 3 months | Ultrasonography: Study of the synovial effusion degree (if any) measured in the longitudinal axis of the suprapatellar recess of the affected knee.Results are expressed as change from baseline in mm. |
| Pain assessment (VAS) | 3 months | Time evolution of pain intensity as measured by Visual Analogue Scale (mm). |
| SF-36 Health questionnaire | 3 months | Questionnaire SF36-v2 to measure physical and mental health. |
| Change from baseline in isokinetic assessment of muscular strength (other conditions) | 3 months | Change from baseline of peak torque (Nm), power mean (W) and total work (J) of the affected joint in extension at 180º/sec, and in flexion at 240º/sec and 180º/sec. |
| Subjective evaluation of the intervention | 3 months | Questionnaire to evaluate the subjective perception of the efficacy of the intervention. |
| Change from baseline in systolic blood pressure, hearth rate, general biochemical profile and body mass index at 3 months | 3 months | Safety assessment includes an evaluation at 3 months of changes from baseline on systolic blood pressure, hearth rate, general biochemical profile and body mass index |
| Number of Participants with Adverse Events | 3 months | The safety assessment includes a register of the appearance of adverse events along the 3 months of the study |
Countries
Spain
Outcome results
None listed